Immunotherapy is the first-line therapy for esophageal squamous cell carcinoma (ESCC), yet many patients do not respond due to drug resistance and the lack of reliable predictive markers. We collected 73 ESCC patients (including discovery cohort and validation cohort) without immune thrombocytopenia and undergoing anti-PD1 immunotherapy. Proteomic and phosphoproteomic analysis of 73 ESCC treatment-naive samples by mass spectrometry-based label-free quantification were applied to explore the potential resistant and sensitive mechanisms, and identify predictive markers of ESCC immunotherapy. Comparative analysis found the pathways related to immune and mitochondrial functions were associated with ESCC immunotherapy sensitivity; while platelet activation bioprocess showed negative correlation with CD8+ T cells and related to ESCC immunotherapy non-sensitivity. Finally, we identified 10 ESCC immunotherapy predictive biomarkers with high accuracy (≥ 0.90) to predict the immunotherapeutic response, which was validated in the independent cohort.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10943778 | PMC |
| http://dx.doi.org/10.1186/s13045-024-01534-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unravelling the Difference of Immune Microenvironment Characteristics between Esophageal Basaloid Squamous Cell Carcinoma and Conventional Esophageal Squamous Cell Carcinoma.
Hum Pathol
January 2025
Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China; Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai 200032, P. R. China. Electronic address:
Objectives: Esophageal basaloid squamous cell carcinoma (basaloid ESCC) is an uncommon variant of esophageal squamous cell carcinoma (ESCC). We characterized the tumor immune microenvironment features of basaloid ESCC, and compared them with conventional ESCC.
Methods And Results: One hundred and four basaloid ESCC patients and 55 conventional ESCC patients were included in Cohort 1.
Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort.
Radiat Oncol
January 2025
Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, P.R. China.
Aim: To characterize the differences of dynamic changes for absolute lymphocyte count (ALC) among esophageal squamous cell carcinoma (ESCC) patients treated with neoadjuvant chemoradiotherapy (nCRT) with or without pembrolizumab, as well as to investigate the clinical and lymphocyte-related organs dosimetric parameters that would impact ALC nadir during nCRT.
Materials And Methods: A total of 216 ESCC patients who received nCRT (with pembrolizumab 144; without pembrolizumab: 72) were identified from a prospective cohort. Weekly and 1-month post-nCRT ALC were identified.
Efficacy and Safety of Immune Checkpoint Inhibitor Rechallenge in the Treatment of Esophageal Squamous Cell Cancer.
J Cancer
January 2025
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Rechallenge with immune checkpoint inhibitors (ICI) shows promise in various cancers, but data in esophageal squamous cell carcinoma (ESCC) is limited. This study aimed to evaluate the efficiency and safety of ICI rechallenge in ESCC. This multicenter study analyzed ESCC patients rechallenged with ICI from January 2020 to March 2023 across two medical institutions.
View Article and Find Full Text PDFEffects of chemoradiotherapy on surface PD-L1 expression in esophageal cancer and its implications for immunotherapy.
Front Immunol
January 2025
Translational Radiobiology Lab, Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Article Synopsis
- Esophageal cancer has a poor prognosis, and while neoadjuvant chemoradiotherapy (CRT) followed by immunotherapy shows promise, the effect of CRT on PD-L1 expression in these cancers is not fully understood.
- The study investigated PD-L1 expression changes in esophageal adenocarcinoma and squamous cell carcinoma cell lines after treatment with chemotherapy and CRT, finding that Carboplatin and CRT led to the highest increases in PD-L1 expression.
- Despite observed increases in PD-L1 with certain treatments, the overall conclusion was that neoadjuvant CRT according to the CROSS protocol did not significantly alter PD-L1 expression when comparing pre- and post-treatment levels in patient samples.
Distinct immune signatures for predicting the immunotherapy efficacy of esophageal squamous cell carcinoma or adenocarcinoma.
Cancer Immunol Immunother
January 2025
Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are distinct histological subtypes of esophageal cancer. The tumor microenvironment of each subtype significantly influences the efficacy of immunotherapy. However, the characteristics of the tumor microenvironments of both subtypes, as well as their specific impacts on immunotherapy outcomes, still require further elucidation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!